- Home
- ANTA vs CVRX Comparison
ANTA vs CVRX Comparison
Compare ANTA & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ANTA | CVRX |
|---|---|---|
| Founded | 2022 | 2000 |
| Country | Singapore | United States |
| Employees | N/A | 223 |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.3M | 81.3M |
| IPO Year | 2024 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ANTA | CVRX |
|---|---|---|
| Price | $3.45 | $2.92 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $16.17 | $10.50 |
| AVG Volume (30 Days) | 5.4K | ★ 1.0M |
| Earning Date | 06-16-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $56,651,000.00 |
| Revenue This Year | $21.95 | $17.17 |
| Revenue Next Year | $30.46 | $17.69 |
| P/E Ratio | $19.77 | ★ N/A |
| Revenue Growth | N/A | ★ 10.45 |
| 52 Week Low | $3.00 | $2.20 |
| 52 Week High | $13.82 | $11.30 |
Technical Indicators
Market Signals| Indicator | ANTA | CVRX |
|---|---|---|
| Relative Strength Index (RSI) | 41.73 | 38.03 |
| Support Level | $3.00 | $2.20 |
| Resistance Level | $4.19 | $3.33 |
| Average True Range (ATR) | 0.29 | 0.21 |
| MACD | 0.00 | 0.08 |
| Stochastic Oscillator | 8.64 | 21.01 |
Price Performance
Historical ComparisonAbout ANTA Antalpha Platform Holding Company Ordinary Shares
Antalpha Platform Holding Co provides financing, technology and risk management solutions to institutional and corporate customers in the crypto asset industry. The company operates through Antalpha Prime platform in the following areas: Supply chain financing and Technology and services. Its revenue prominently consists of technology financing fees charged on the supply chain loans.
About CVRX CVRx Inc.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.